Industry Overview

Chronic gonadotropin market was valued at $1.0 billion in 2025 and is projected to reach $1.8 billion by 2035, growing at a CAGR of 6.3% during the forecast Period (2026-2035). The market is driven by increasing infertility rates and growing adoption of assisted reproductive technologies (ART) worldwide. Chronic gonadotropins, particularly human chorionic gonadotropin (hCG), are widely used for ovulation induction, IVF, and male infertility treatments. The market benefits from advancements in recombinant formulations, improving safety, purity, and dosing accuracy. Hospitals, medical centers, and specialized fertility clinics are the primary end-users. The US leads the market, supported by strong healthcare infrastructure, regulatory oversight, and high ART adoption.

Market Dynamics

Rising Prevalence of Infertility and Demand for Reproductive Treatments

A primary driver of the global chronic gonadotropin market is the increasing incidence of infertility globally, which has led to greater demand for fertility?related hormonal therapies. Chronic gonadotropin, particularly human chorionic gonadotropin (hCG), is essential in ovulation induction and is widely used in assisted reproductive technologies (ART) such as in?vitro fertilization (IVF) and intra?uterine insemination (IUI). Factors such as delayed childbearing, lifestyle stressors, and hormonal imbalances have contributed to infertility rates rising globally, prompting more couples to seek medical intervention and boosting demand for chronic gonadotropin therapies. This trend has been a foundational growth driver over recent years and continues to propel market expansion as more patients and clinicians adopt these treatments.

Expansion of Assisted Reproductive Technologies and Therapeutic Awareness

The growing adoption and availability of assisted reproductive technologies (ART), alongside increasing awareness among healthcare providers and patients about hormonal therapy options, significantly fuels market growth. Clinics in emerging and developed economies are offering advanced fertility solutions, which rely on chronic gonadotropins to stimulate ovulation and support successful conception. Additionally, expanding awareness about male infertility treatments (such as therapy for hypogonadism and oligospermia) and the use of hCG in broader hormone regulation applications further enhances uptake. As both public knowledge and clinical acceptance improve, the therapeutic landscape widens and boosts overall demand for chronic gonadotropin products.

Technological Advancements and Broader Clinical Applications

Technological progress in product development and expanding clinical applications are also driving the market. Innovations such as recombinant chorionic gonadotropin formulations increase product purity, safety, and dosing flexibility, making treatments more effective and appealing to clinicians and patients alike. Beyond fertility, chronic gonadotropin is being explored for its roles in testosterone regulation therapies and other endocrine treatments, expanding its use beyond traditional reproductive health. Rising investments in biotechnology and research into improved hormone therapies support continued innovation, creating additional opportunities for growth across therapeutic segments.

Market Segmentation

• Based on the type, the market is segmented into human chronic gonadotropin and animal chronic gonadotropin
• Based on the technology, the market is segmented into female infertility treatment, oligospermia treatment, cryptorchidism treatment, and others.
• Based on the end-user, the market is segmented into hospitals, medical centres, and others.

Female Infertility Treatment Segment to Grow at a Considerable Market Share

The female infertility treatment segment under the technology category stands out as the largest and leading contributor to market revenue and growth. This dominance is primarily owing to human chronic gonadotropin (hCG) therapies are extensively used to induce ovulation and support assisted reproductive procedures, such as in vitro fertilization (IVF) and other fertility treatments, addressing the growing prevalence of infertility in women worldwide. The rising incidence of infertility due to delayed childbearing, lifestyle factors, and greater patient awareness has significantly boosted demand for hCG?based infertility therapies more than other treatment applications like oligospermia or cryptorchidism.

Female infertility treatment not only accounts for the largest market share among the therapeutic/technology segments but also drives overall chronic gonadotropin demand, because reproductive clinics and hospitals frequently administer these hormones as part of standardized fertility protocols. As more couples seek effective fertility solutions and the accessibility of fertility care expands globally, this segment continues to pull ahead of end?user categories (like hospitals or medical centers) and product types (human vs. animal chronic gonadotropin) in terms of both market size and growth influence.

Human Chronic Gonadotropin (hCG): A Key Segment in Market Growth

The human chronic gonadotropin (hCG) segment is the key growth driver in the global chronic gonadotropin market. This segment dominates due to its extensive use in fertility treatments, particularly in assisted reproductive technologies (ART) such as in?vitro fertilization (IVF) and intra?uterine insemination (IUI). hCG plays a crucial role in stimulating ovulation and supporting luteal phase function, making it indispensable in clinical protocols for female infertility. The rising prevalence of infertility worldwide, driven by factors such as delayed childbearing, lifestyle stress, and hormonal imbalances, has significantly increased the demand for human chronic gonadotropin therapies.

Additionally, the hCG segment benefits from advancements in recombinant DNA technology, which have improved product purity, safety, and dosing accuracy, further encouraging clinicians to prefer these formulations over animal-derived alternatives. Moreover, hCG is increasingly used in male infertility treatments, such as addressing hypogonadism and oligospermia, broadening its clinical applications. The combination of growing patient awareness, expanding ART adoption, and technological innovation positions human chronic gonadotropin as the most lucrative segment, capturing the majority of market growth in both developed and emerging regions. Its clinical versatility and established efficacy make it the cornerstone of the chronic gonadotropin market’s expansion.

Regional Outlook

The global chronic gonadotropin market is further divided by geography, including North America (the US and Canada), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Region to Hold a Substantial Growth Rate

In North America, the US dominates the global chronic gonadotropin market, holding a major share due to its well-established healthcare infrastructure, high prevalence of infertility, and widespread adoption of assisted reproductive technologies (ART). The country has a significant number of fertility clinics and specialized medical centers offering treatments such as in?vitro fertilization (IVF), intra?uterine insemination (IUI), and ovulation induction, all of which rely heavily on human chronic gonadotropin (hCG) therapies. Rising awareness about infertility and growing acceptance of fertility interventions among both men and women further drive the demand for chronic gonadotropins.

Additionally, the US benefits from advanced research and development in reproductive medicine, including innovations in recombinant hCG formulations that provide higher purity, safety, and consistent efficacy. Government support and favorable insurance coverage for certain fertility treatments also encourage patients to pursue these therapies, reinforcing the country’s leading position. Furthermore, the robust biopharmaceutical industry in the US ensures a steady supply, quality standards, and regulatory compliance, strengthening market confidence. Collectively, these factors, including high treatment adoption, advanced R&D, supportive healthcare policies, and growing patient awareness, make the US the key country dominating the global chronic gonadotropin market, serving as a benchmark for both clinical practice and market growth globally

Market Players Outlook

The major companies operating in the global chronic gonadotropin market include Ferring Pharmaceuticals, Fresenius Kabi AG, Merck KGaA, Organon & Co., Sun Pharmaceutical Industries Ltd., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisitions to expand their businesses and develop innovative products to maintain their market positioning.

Recent Development

• In March 2025, Ferring BV received approval from the European Medicines Agency (EMA) for a new long?acting recombinant human chorionic gonadotropin (r?hCG) formulation designed to reduce the frequency of injections required in IVF and other fertility protocols, improving patient compliance and convenience.
• In 2024, Ferring Pharmaceuticals launched an upgraded formulation of hCG intended to enhance bioavailability and clinical effectiveness in assisted reproductive technology (ART) regimens, which has been adopted across major clinics in North America and Europe.

The Report Covers

• Market value data analysis for 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global Chronic Gonadotropin market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.